Management


Ori Choshen

Ori Choshen

CEO

Ori  brings with him extensive, multidisciplinary experience in building innovation platforms and establishing, investing in and mentoring innovative startups in the life sciences, pharma, AI, and hitech industries. Ori has a broad range of experience in senior management and business development in these areas.

Prior to joining VLX Ventures in 2013, Ori served as VP Business Development at Xenia VC and as a Director of Business Development at SanDisk, (NSDQ: SNDK) where he managed the Ecosystem Group. Ori joined SanDisk as part of the company’s $1.6 billion acquisition of M-Systems (NSDQ: FLSH) in 2006. Prior to this, Ori held business development and management positions at M-Systems and Hutchison’s global telecom group, managing the Handset Department (Marketing) of Orange Israel, a Hutchison’s subsidiary.

Ori also served as an investment manager in PFC, Orange’s VC subsidiary. Ori holds a B.A. in Philosophy, Cum Laude, and an LLB degree from Tel Aviv University as well as an MBA, Cum Laude, from the Solvay Business School in Brussels.

Dr. Nadav Klein

Dr. Nadav Klein

CTO

Nadav brings with him a diverse range of experience as a technology expert and researcher in both industry and academia. Nadav is versed in building, managing, and nurturing technology driven teams and startups in the Information Technology, Agtech, and Life Science space.

Nadav’s keen interest and proficiency in Healthcare, Bioinformatics and Artificial Intelligence applications drove him to pursue a rich academic background, spanning a wide range of multifaceted research fields, most notably Computational Biology, Genomics, Bioinformatics, Precision Agriculture, Advanced Data Science, Robotics, Renewable Energy, and Precision Medicine.

His unique ability to combine technological expertise, deep science competence and a strong business acumen is exceptionally rare, even more so in the Venture Capital realm, constituting a significant asset to VLX’s portfolio companies. Nadav holds both a PhD in Bioinformatics from the University of California-Davis, with honors and distinction, and a BSc in Bioinformatics from Tel Aviv University, Magna Cum Laude. He shares his knowledge as a lecturer at the Interdisciplinary Center in Herzliya, Tel Aviv University, and the Technion.

Dr. Lior Carmon

Dr. Lior Carmon

CIO

Lior  is an expert in the fields of  immunology, specifically vaccinology and immune oncology. Holding a PhD and an MBA, he has an in depth understanding of the science and business trends in these markets. Lior is a pioneer in the signal peptide domain, influencing the development of superior vaccines. Over the past 20 years, Lior serves as an investor, entrepreneur and executive at key Israeli biotech companies including VaxilBio, BIoKine, CureTech and Ester Neurosciences.

He has held various positions at Clal biotechnology industries (CBI) fund, culminating his tenure as a VP of Strategic Alliances & Technology Assessment. During his time at CBI, he was a first point of assessment and decision for investment opportunities in all sectors and at all stages of development. He is a founder, CEO, and head of R&D at VaxilBio Ltd. which developed the SPD-based cancer vaccine, ImMucin, and the tuberculosis subunit vaccine, MTBuVax. His work includes 7 publications including a review.

He is also a co-founder and VP of Business Development at two companies in the immune oncology field, Biokine (lead product: BL-8040) and CureTech (lead product: CT011). Lior currently serves as a founder and CEO of Biopharma Investment & Management, a boutique consultancy company. Lior’s MSc Degree is from Tel-Aviv University and his PhD is from the WIS Institute in the field of tumor immunology, specializing in the development of cancer vaccines.

Eli Sorzon

Eli Sorzon

CFO

Eli  has 13 years experience in accounting and finance, mainly for large publicly traded hi-tech companies. He is a CPA and holds a bachelor’s degree in Business Administration from the College of Management Academic Studies Division.
Prior to joining Xenia in 2007:
• Manager with the accounting firm of Deloitte Brightman Almagor.
• Manager with Goldstein Sabo Tevet, a leading Tel Aviv accounting firm specializing in hi-tech companies traded on NASDAQ and TASE.